XRHealth, the leader in extended reality and therapeutic applications, announces a new VR therapy application for ADHD.
BOSTON, Sept. 22, 2020 /PRNewswire/ -- XRHealth, the leader in extended reality and therapeutic applications, announces a new VR therapy application for ADHD. The application is aimed to improve well known ADHD cognitive functioning such as attention, impulsivity and higher, more complex thinking functions such as: initiating, organizing, planning and fully executing daily tasks. The VR solution closely monitors user progress based on sustained focus while distractions are present. A new FDA policy enables clinicians to prescribe VR therapy for patients with ADHD during the public health emergency of COVID-19 as an adjunct to clinician-supervised outpatient treatment. The VR training solution is based on the brain plasticity principle, which is the brain’s ability to restructure itself in attempt to overcome existing challenges. The application uses well based cognitive principles shown in the research field that are effective in facilitating this process. To further enhance its effectiveness, the application allows the clinician to create, monitor, and adjust the training process at every step. In every training session a user-adaptive mechanism, backed by eye-tracking technology, is available to allow the clinician to adjust the task difficulty level in accordance with the patient’s ability. This mechanism is meant to challenge patients and constantly motivate them to enhance their performance. “Our training method is able to help a child or adult brain better cope with ADHD,” said Eran Orr, CEO of XRHealth. “The interactive nature of the therapy is able to give clinicians critical measurements of improved concentration and attention span as well as reduced impulsivity.” Clinicians using the XRHealth VR training method will prescribe the number and length of VR therapy sessions for each individual ADHD patient. Some of the application’s core advantages, include:
The therapeutic platform will be available to consumers later this year on the XRHealth web site. The XRHealth platform is not intended to represent a substitution for a patient’s medication, and any recommendations provided by the application are supportive in nature and should not be solely or primarily relied upon to treat ADHD. About XRHealth: CONTACT: DeeDee Rudenstein, 267-521-9654, drudenstein@propelsc.com
SOURCE XRHealth |